Theravance Biopharma Inc. (TBPH)
Theravance Biopharma Statistics
Share Statistics
Theravance Biopharma has 50M shares outstanding. The number of shares has increased by 1.72% in one year.
| Shares Outstanding | 50M |
| Shares Change (YoY) | 1.72% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | 91.54% |
| Shares Floating | 45.89M |
| Failed to Deliver (FTD) Shares | 415 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 3.6M, so 7.32% of the outstanding shares have been sold short.
| Short Interest | 3.6M |
| Short % of Shares Out | 7.32% |
| Short % of Float | 14.22% |
| Short Ratio (days to cover) | 14.95 |
Valuation Ratios
The PE ratio is -8.15 and the forward PE ratio is -9.67. Theravance Biopharma's PEG ratio is -0.54.
| PE Ratio | -8.15 |
| Forward PE | -9.67 |
| PS Ratio | 7.14 |
| Forward PS | 2.1 |
| PB Ratio | 2.62 |
| P/FCF Ratio | -38.73 |
| PEG Ratio | -0.54 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Theravance Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.28.
| Current Ratio | 5.02 |
| Quick Ratio | 5.02 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | -1.06 |
| Debt / FCF | -4.2 |
| Interest Coverage | -18.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $663.72K |
| Profits Per Employee | $-581.63K |
| Employee Count | 97 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 11.8M |
| Effective Tax Rate | -26.46% |
Stock Price Statistics
The stock price has increased by 10.89% in the last 52 weeks. The beta is 0.14, so Theravance Biopharma's price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | 10.89% |
| 50-Day Moving Average | 9.18 |
| 200-Day Moving Average | 9.02 |
| Relative Strength Index (RSI) | 72.65 |
| Average Volume (20 Days) | 238.45K |
Income Statement
In the last 12 months, Theravance Biopharma had revenue of 64.38M and earned -56.42M in profits. Earnings per share was -1.15.
| Revenue | 64.38M |
| Gross Profit | 64.38M |
| Operating Income | -46.95M |
| Net Income | -56.42M |
| EBITDA | -46.95M |
| EBIT | -47.16M |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
The company has 37.8M in cash and 49.82M in debt, giving a net cash position of -12.02M.
| Cash & Cash Equivalents | 37.8M |
| Total Debt | 49.82M |
| Net Cash | -12.02M |
| Retained Earnings | -965.52M |
| Total Assets | 354.16M |
| Working Capital | 128.98M |
Cash Flow
In the last 12 months, operating cash flow was -11.54M and capital expenditures -332K, giving a free cash flow of -11.87M.
| Operating Cash Flow | -11.54M |
| Capital Expenditures | -332K |
| Free Cash Flow | -11.87M |
| FCF Per Share | -0.24 |
Margins
Gross margin is 100%, with operating and profit margins of -72.92% and -87.63%.
| Gross Margin | 100% |
| Operating Margin | -72.92% |
| Pretax Margin | -69.3% |
| Profit Margin | -87.63% |
| EBITDA Margin | -72.92% |
| EBIT Margin | -72.92% |
| FCF Margin | -18.43% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TBPH is $10, which is -3.8% lower than the current price. The consensus rating is "Hold".
| Price Target | $10 |
| Price Target Difference | -3.8% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -1.95 |
| Piotroski F-Score | 5 |